Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C20H23FN4O3.CH4O3S |
| Molecular Weight | 482.526 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CS(O)(=O)=O.CC1=C(N2C[C@@H](N)C3(CC3)C2)C(F)=C(N)C4=C1N(C=C(C(O)=O)C4=O)C5CC5
InChI
InChIKey=QCRMQMNCFYYEFX-UTONKHPSSA-N
InChI=1S/C20H23FN4O3.CH4O3S/c1-9-16-13(18(26)11(19(27)28)6-25(16)10-2-3-10)15(23)14(21)17(9)24-7-12(22)20(8-24)4-5-20;1-5(2,3)4/h6,10,12H,2-5,7-8,22-23H2,1H3,(H,27,28);1H3,(H,2,3,4)/t12-;/m1./s1
DescriptionCurator's Comment: description was created based on several sources, including http://adisinsight.springer.com/drugs/800006301 | http://www.ncbi.nlm.nih.gov/pubmed/12957636 | https://www.ncbi.nlm.nih.gov/pubmed/15608441
Curator's Comment: description was created based on several sources, including http://adisinsight.springer.com/drugs/800006301 | http://www.ncbi.nlm.nih.gov/pubmed/12957636 | https://www.ncbi.nlm.nih.gov/pubmed/15608441
Olamufloxacin (HSR-903) is an oral fluoroquinolone antimicrobial agent which has been reported to have a potent activity against respiratory pathogens, such as Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, Klebsiella pneumoniae, Staphylococcus aureus, Chlamydia spp. and Legionella spp., as well. Olamufloxacin inhibits DNA gyrase from the susceptible and resistant bacterial strains. It has been shown that olamufloxacin possesses a more potent antibacterial activity against potential respiratory pathogens compared with other quinolone derivatives. An oral formulation of olamufloxacin was undergoing phase III for Bacterial infections in Japan (Discontinued).
CNS Activity
Curator's Comment: Known to be CNS penetrant in rats. Human data is not available. Tissue-to-plasma concentration ratio (Kp) in brain is extremely low, 0.11, demonstrating very poor distribution to the brain compared with other tissues. The blood-brain barrier permeability coefficient of [14C]Olamufloxacin ([14C]HSR-903) at a very low concentration (5 μm) was 10.5 μl/min/g. When the concentration of HSR-903 was increased to 20 or 50 mM, the permeability coefficient was increased 3- to 4-fold.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2311224 |
20.7 µM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Curative | Unknown Approved UseUnknown |
|||
| Curative | Unknown Approved UseUnknown |
|||
| Curative | Unknown Approved UseUnknown |
|||
| Curative | Unknown Approved UseUnknown |
|||
| Curative | Unknown Approved UseUnknown |
|||
| Curative | Unknown Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Hepatobiliary transport kinetics of HSR-903, a new quinolone antibacterial agent. | 1998 Nov |
|
| Effect of HSR-903, a new fluoroquinolone, on the concentration of theophylline in serum. | 1999 Jun |
|
| Susceptibility of Yersinia pestis to novel and conventional antimicrobial agents. | 2003 Aug |
|
| In vitro and in vivo activity of olamufloxacin (HSR-903) against Legionella spp. | 2003 Dec |
Patents
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID20168419
Created by
admin on Sat Dec 16 05:14:40 GMT 2023 , Edited by admin on Sat Dec 16 05:14:40 GMT 2023
|
PRIMARY | |||
|
9826542
Created by
admin on Sat Dec 16 05:14:40 GMT 2023 , Edited by admin on Sat Dec 16 05:14:40 GMT 2023
|
PRIMARY | |||
|
5Z27G7LBZV
Created by
admin on Sat Dec 16 05:14:40 GMT 2023 , Edited by admin on Sat Dec 16 05:14:40 GMT 2023
|
PRIMARY | |||
|
167888-07-5
Created by
admin on Sat Dec 16 05:14:40 GMT 2023 , Edited by admin on Sat Dec 16 05:14:40 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD
